Table 2.
Patients characteristics and main study results for AKT and MAPK immunohistochemistry in metastases
| Mets Group (n = 37) | AKT positive (n = 23) | AKT negative (n = 14) | pvalue | MAPK positive (n = 20) | MAPK Negative (n = 17) | pvalue | |
|---|---|---|---|---|---|---|---|
|
Age (range) |
66 (36–80) |
67 (36–79) |
65 (38–80) |
ns |
65 (40–80) |
66 (40–79) |
ns |
|
Sex |
|
|
|
|
|
|
|
| Males |
27 (73%) |
15 (65%) |
12 (85%) |
ns |
13 (60%) |
14 (82) |
ns |
| Females |
10 (27%) |
8 (35%) |
2 (15%) |
ns |
7 (40%) |
3 (18%) |
ns |
|
ECOG PS |
|
|
|
|
|
|
|
| 0–1 |
28 (76%) |
17 (74%) |
11 (78%) |
ns |
16 (80%) |
12 (70%) |
ns |
| 2–3 |
9 (24%) |
6 (26%) |
3 (22%) |
ns |
4 (20%) |
5 (30%) |
ns |
|
Metastatic sites |
|
|
|
|
|
|
|
| 1 |
10 (27%) |
6 (26%) |
4 (28%) |
ns |
5 (25%) |
5 (29%) |
ns |
| ≥ 2 |
27 (73%) |
17 (74%) |
10 (72%) |
ns |
15 (75%) |
12 (71%) |
ns |
|
Previous lines of treatment |
|
|
|
|
|
|
|
| 1 |
9 (24%) |
5 (22%) |
4 (28%) |
ns |
5 (25%) |
4 (23%) |
ns |
| ≥ 2 |
28 (76%) |
18 (78%) |
10 (72%) |
ns |
15 (75%) |
13 (77%) |
ns |
|
Treatment |
|
|
|
|
|
|
|
| mFOLFIRI + Cetuximab |
12 (32%) |
6 (26%) |
6 (43%) |
ns |
7 (35%) |
5 (30%) |
ns |
| Irinotecan + Cetuximab |
25 (68%) |
17 (74%) |
8 (57%) |
ns |
13 (65%) |
12 (70%) |
ns |
|
Response Rate |
|
|
|
|
|
|
|
| PR |
10 (27%) |
2 (9%) |
8 (58%) |
0.004 |
2 (10%) |
8 (47%) |
0.002 |
| SD |
9 (25%) |
6 (26%) |
3 (21%) |
ns |
5 (25%) |
4 (23%) |
ns |
| PD |
18 (48%) |
15 (65%) |
3 (21%) |
0.001 |
13 (65%) |
5 (30%) |
0.006 |
|
Survival |
|
|
|
|
|
|
|
| m PFS (months) |
3.2 |
2.3 |
9.2 |
<0.0001 |
2.3 |
8.6 |
<0.0001 |
| m OS (months) | 12.6 | 6.1 | 26.7 | <0.0001 | 7.8 | 26 | 0.0004 |
ns = not significant
ECOG PS = Eastern cooperative oncology croup performance score
mFOLFIRI = modified FOLFIRI (irinotecan 180 mg/sqm d1, 5FU bolus 400 mg/sqm d1, 5FU 2400 mg/sqm continuous infusion for 46 hrs;
PR = partial remission;
SD = stable disease;
PD = progressive disease;
m PFS = median progression-free survival;
m OS = median overall survival.